ReviewCNS neuroscience & therapeutics2016
Role of Donepezil in the Management of Neuropsychiatric Symptoms in Alzheimer's Disease and Dementia with Lewy Bodies.
Review in CNS neuroscience & therapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 2 syntheses or guidelines pooled it, 125 citations in OpenAlex.
- Psychiatric Adverse Events of Acetylcholinesterase Inhibitors in Alzheimer's Disease and Parkinson's Dementia: Systematic Review and Meta-Analysis.Drugs & aging · 2023Pooled it
- Is Qi Fu Yin effective in clinical treatment of dementia?: A meta-analysis of 697 patients.Medicine · 2021Pooled it
- Donepezil for Fatigue and Psychological Symptoms in Post-COVID-19 Condition: A Randomized Clinical Trial.JAMA network open · 2025Trial
- [Polypharmacy in patients with neuropsychiatric symptoms].Innere Medizin (Heidelberg, Germany) · 2026Article
- A venom fraction from the Philippine tarantula (The journal of venomous animals and toxins including tropical diseases · 2026Article
- Core Clinical Features Associated With Survival in Patients With Dementia With Lewy Bodies.Neurology · 2025Article
- Sex-specific effects of neuromodulatory drugs on normal and stress-induced social dominance and aggression in rats.Psychopharmacology · 2025Article
- Behavioral disorders in dementia with Lewy bodies: old and new knowledge.Journal of neural transmission (Vienna, Austria : 1996) · 2025Review
- Housing status is protective of neuropsychiatric symptoms among dementia-free multi-ethnic Asian elderly.BMC geriatrics · 2024Article
- Review
- Progress in Pharmacologic Management of Neuropsychiatric Syndromes in Neurodegenerative Disorders: A Review.JAMA neurology · 2024Review
- Antidementia Medication Use in Nursing Home Residents.Journal of geriatric psychiatry and neurology · 2024Article
- Multifunctional Nanocarriers for Alzheimer's Disease: Befriending the Barriers.Molecular neurobiology · 2024Review
- Manasamitra Vatakam on Scopolamine-Induced Amnesia in Female Wistar Rats.Journal of pharmacy & bioallied sciences · 2024Article
- Novel Pitolisant-Derived Sulfonyl Compounds for Alzheimer Disease.International journal of molecular sciences · 2024Article
- Behavioral disinhibition in stroke.Frontiers in neurology · 2024Article
- Sexually Dimorphic Effects of Neuromodulatory Drugs on Normal and Stress-Induced Social Interaction in Rats.Brain sciences · 2023Article
- The Case for a Novel Therapeutic Approach to Dementia: Small Molecule Hepatocyte Growth Factor (HGF/MET) Positive Modulators.Journal of Alzheimer's disease : JAD · 2023Review
- Potentially Inappropriate Medications Pre- and Post-Diagnosis of Major Neurocognitive Disorders Among Older People in Sweden: A Register-Based, 6-Year Longitudinal Study.Drugs & aging · 2022Article
- Exploring the Recent Trends in Management of Dementia and Frailty: Focus on Diagnosis and Treatment.Current medicinal chemistry · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 5 countries.
Funding
Abstract
Alzheimer's disease (AD) is a progressive condition that affects cognition, function, and behavior. Approximately 60-90% of patients with AD develop neuropsychiatric symptoms (NPS) such as hallucinations, delusions, agitation/aggression, dysphoria/depression, anxiety, irritability, disinhibition, euphoria, apathy, aberrant motor behavior, sleep disturbances, appetite and eating changes, or altered sexual behavior. These noncognitive behavior changes are thought to result from anatomical and biochemical changes within the brain, and have been linked, in part, to cholinergic deficiency. Cholinesterase inhibitors may reduce the emergence of NPS and have a role in their treatment. These agents may delay initiation of, or reduce the need for, other drugs such as antipsychotics. This article summarizes the effects of donepezil, a cholinesterase inhibitor, on the NPS of dementia with emphasis on AD and dementia with Lewy bodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.